Health Care·Biotechnology·$7.7B
Halozyme Therapeutics (HALO) is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases. With a market cap of $8 billion, it plays a significant role in the health care sector, particularly in enhancing drug delivery methods and improving patient outcomes.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
Revenue growth reflects the company's ability to generate sales and is crucial for assessing its market performance.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
88%
Avg EPS Surprise
+7.71%
Avg Stock Reaction
+0.25%
In Q4 2025, Halozyme reported an unexpected EPS loss of $-0.24, significantly missing analyst estimates. Despite this, the stock saw a slight increase of 1.31% the following day.
Management Promises & Guidance
Analysts expect Halozyme to report a rebound in earnings this quarter, with a consensus EPS of $1.52. Investors are looking for signs of recovery after a disappointing last quarter.
Bull Case
If Halozyme meets or exceeds EPS expectations, it could signal a strong recovery and renewed investor confidence, potentially driving the stock higher.
Bear Case
Conversely, if the company fails to meet earnings expectations again, it may lead to further declines in investor sentiment and stock price.
Earnings Per Share (EPS)
$1.52EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
$359MRevenue growth reflects the company's ability to generate sales and is crucial for assessing its market performance.
The print will turn on these two things.
Q1
Will Halozyme achieve an EPS of at least $1.52 this quarter?
Meeting or exceeding this EPS target is crucial for restoring investor confidence after the previous quarter's miss.
Q2
What specific revenue growth can we expect, particularly in key therapeutic areas?
Understanding revenue performance in critical segments will help gauge the company's market position and future potential.
Why consensus could be wrong
The Street may be underestimating the potential for Halozyme to rebound from its last quarter's performance, especially given its strong historical EPS beat rate.
Supporting Evidence
Halozyme has an 88% EPS beat rate historically, indicating a strong likelihood of exceeding expectations.
The average reaction to earnings beats has been positive, suggesting that the market may be too cautious.
Recent operational improvements and product pipeline developments could drive better-than-expected results.
Key Risk
If revenue growth exceeds $359M, it could significantly alter the market's perception of the company's recovery potential.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it follows a significant earnings miss, and the market is keenly watching for signs of recovery.
Bull Confirmed If
Achieving an EPS of $1.52 or better would confirm a strong recovery and positive momentum.
Bear Confirmed If
An EPS below $1.42 would raise concerns about ongoing profitability issues.
Implied Move
±N/A
There is no options market data available to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Halozyme beats expectations, history suggests a potential average increase of around 0.10%, confirming a positive turnaround.
In-Line / Cautious
If results are in line but cautious commentary is provided, the stock may react neutrally, reflecting uncertainty.
Miss
A miss could lead to a decline, with history indicating an average drop of around 1.31% following earnings misses.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026